Constellation Pharma closes $32M funding

USA-based Constellation Pharmaceuticals, which claims to be the first biopharmaceutical company focused on discovering and developing novel drugs targeting selective regulators of epigenetic function, has closed a $32.0 million series A financing. The proceeds will be used to establish the discovery platform and accelerate the development of a preclinical candidate pipeline of epigenetic-targeted drugs.

Constellation Pharmaceuticals was founded by three of the foremost authorities and leaders within the field of epigenetics: Danny Reinberg, professor of biochemistry at the New York University School of Medicine and an Investigator of the Howard Hughes Institute; Yang Shi, professor of pathology at the Harvard Medical School and David Allis, professor and head of the Laboratory of Chromatin Biology at the Rockefeller University.

Epigenetics is a new field of biology that involves